Omega-3 manufacturers Epax Norway has received just under €750,000 in funding for research looking into the role of less well-known fatty acids in brain health, eye health, skin health and fertility.
Norwegian firm Epax is to invest €32m over the next two years in upgrading its facilities and capacity in response to consumer demand for high-potency omega-3 oils.
Mid-last year the chief of Norwegian omega-3 player EPAX told us, “We are the last of the big omega-3 independents.” Soon after US agri-food company FMC had snapped it up for $350m. Here FMC Nutraceuticals general manager Daniel H. Rosenbaum talks through...
In a reverse of what we see in nature - krill gobbling up fish - Trygg Pharma has entered into an agreement to purchase Epax Holding AS from Austevoll Seafood.
Austevoll has completed its acquisition of EPAX from Ferd Private
Equity for an undisclosed sum, securing the omega-3 company's fish
oil supply and enabling full traceability.
Norway's Epax has announced it has gained approval from Australia's
Therapeutic Goods Administration (TGA) to provide high
concentration omega-3 to the Australian market.
The omega-3 market is one of the biggest trends in the supplement
market today, but it seems it is crossing from general wellness
towards products aimed at specific consumers and indications.